Analyzing...
Loading company...
NATCO Pharma Ltd. engages in the business of pharmaceuticals with research, manufacturing and marketing of finished dosage formulations and active pharmaceutical ingredients. The company is headquartered in Hyderabad, Telangana. The firm is engaged in the business of pharmaceuticals, which comprises research and development, manufacturing and selling of bulk drugs and finished dosage formulations. The firm deals in the production of finished dosage formulations (FDF), which it sells in India, the United States and the Rest of the World, as well as active pharmaceutical ingredients (APIs). Its capabilities include multi-step synthesis, semi-synthetic fusion technologies, production of high-potency APIs and peptides. The firm operates through two segments: pharmaceuticals and agrochemicals. The pharmaceuticals segment, the Company drives its sales through FDFs and APIs. The agrochemicals segment is focused on niche products, including pest management.
No significant concerns identified
Nothing flagged for monitoring
“Operates in Pharmaceuticals — Formulations & API.”
₹4,078 Cr revenue.
COGS 16.9%, employees 16.9%.
“We'll end the year with about $12.75 to 1,300 crores. More or less consistent with what we have given at the start of the year.”
“Contribution from Revlimid will drop dramatically for next two quarters. Guidance of 750-800 crores for quarter. Bad guidance of 135-150 crores per quarter.”
“Assets increased, went past 10,000 crores this quarter. Balance sheet strength has been dramatic.”
| KPI | Company | Sector Median |
|---|---|---|
| ROE | 15.4%▲ | 10.3% |
| ROCE | 16.3%▲ | 13.7% |
| Net Margin | 32.4%▲ | 7.6% |
| EBITDA Margin | 39.6%▲ | 15.4% |
| Debt To Equity | 0.08x▼ | 0.15x |
| Rev Growth 3yr | 15.9%▲ | 10.0% |
| EPS Growth 3yr | 26.4%▲ | 16.0% |
| (₹ Cr) | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹4,078 Cr -7.9% | ₹4,430 Cr +10.8% | ₹3,999 Cr +47.7% | ₹2,707 Cr +39.2% | ₹1,945 Cr -5.2% | ₹2,052 Cr +7.2% | ₹1,915 Cr -8.6% | ₹2,095 Cr |
| Other Income | ₹298 Cr -16.1% | ₹355 Cr +176.7% | ₹128 Cr +22.5% | ₹105 Cr +5.7% | ₹99 Cr -4.4% | ₹104 Cr -3.5% | ₹107 Cr -17.5% | ₹130 Cr |
| Total Income | ₹4,376 Cr -8.5% | ₹4,784 Cr +15.9% | ₹4,127 Cr +46.8% | ₹2,812 Cr +37.6% | ₹2,044 Cr -5.2% | ₹2,156 Cr +6.6% | ₹2,022 Cr -9.1% | ₹2,225 Cr |
| COGS | ₹691 Cr +0.1% | ₹690 Cr -3.7% | ₹717 Cr +14.2% | ₹627 Cr +11.8% | ₹561 Cr +9.7% | ₹511 Cr +34.0% | ₹382 Cr +7.7% | ₹354 Cr |
| ₹2,885 Cr +15.7% | ₹2,493 Cr +1.6% | ₹2,453 Cr +25.8% | ₹1,950 Cr +5.9% | ₹1,842 Cr +16.8% | ₹1,576 Cr +8.4% | ₹1,454 Cr +3.8% | ₹1,400 Cr | |
| Profit Before Tax | ₹1,491 Cr -34.9% | ₹2,291 Cr +36.9% | ₹1,674 Cr +94.2% | ₹862 Cr +326.3% | ₹202 Cr -65.1% | ₹580 Cr +1.9% | ₹569 Cr -31.0% | ₹825 Cr |
| ₹119 Cr -70.9% | ₹408 Cr +43.1% | ₹285 Cr +94.5% | ₹147 Cr +355.3% | ₹32 Cr -76.5% | ₹137 Cr +24.1% | ₹111 Cr -39.3% | ₹182 Cr | |
| Net Profit | ₹1,419 Cr -24.7% | ₹1,883 Cr +35.7% | ₹1,388 Cr +94.1% | ₹715 Cr +320.8% | ₹170 Cr -61.6% | ₹442 Cr -3.4% | ₹458 Cr -28.7% | ₹642 Cr |
| Profit (Owners) | ₹1,419 Cr -24.8% | ₹1,885 Cr +35.8% | ₹1,388 Cr +94.1% | ₹715 Cr +320.8% | ₹170 Cr -61.4% | ₹441 Cr -4.3% | ₹461 Cr -28.5% | ₹644 Cr |
| Minority Interest | ₹0.00 Cr +100.0% | (₹2 Cr) | ₹0.00 Cr | ₹0.00 Cr | ₹0.00 Cr -100.0% | ₹2 Cr ↑ Recovery | (₹3 Cr) -35.0% | (₹2 Cr) |
| Other Comprehensive Income | ₹287 Cr ↑ Recovery | (₹24 Cr) ↓ Decline | ₹15 Cr +451.9% | ₹3 Cr -94.6% | ₹50 Cr +471.3% | ₹9 Cr ↑ Recovery | (₹15 Cr) -90.8% | (₹8 Cr) |
| EPS | ₹79.20 | ₹105.26 | ₹77.51 | ₹39.20 | ₹9.31 | ₹24.18 | ₹25.31 | ₹35.24 |
| Diluted Shares | ₹18 Cr | ₹18 Cr | ₹18 Cr | ₹18 Cr | ₹18 Cr | ₹18 Cr | ₹18 Cr | ₹18 Cr |
| Profit Or Loss Of Associates | ₹47 Cr | ₹0.00 Cr | ₹0.00 Cr | ₹0.00 Cr | ₹0.00 Cr | ₹0.00 Cr | ₹0.00 Cr | ₹0.00 Cr |
No related party data available for this company.
This section will be populated when data becomes available.
Disclaimer · The Stock Filter is an information platform, not a SEBI-registered investment adviser. All data, scores, and narratives are generated from public filings and AI analysis — they do not constitute investment advice, recommendations, or endorsements. Always consult a qualified financial adviser before making investment decisions. Past performance does not guarantee future results.
Natco Pharma Limited has informed the Exchange regarding a press release dated July 18, 2026, titled "NATCO received Tentative Approval for Olaparib Tablets from the United States Food and Drug Admini...
The Company has informed the Exchange regarding a press release dated July 14, 2026, titled "NATCO Pharma Limited completes acquisition of additional 13.25% stake in Adcock Ingram Holdings Proprietary...
Natco Pharma Limited has informed the Exchange about Action(s) taken or orders passed
Natco Pharma Limited has informed the Exchange regarding Outcome of Board Meeting held on July 08, 2026.
Natco Pharma Limited has informed the Exchange about Mr. Nadella Malleswara Rao, Vice President - Operations, Pharma Division Kothur of the Company has superannuated today i.e., with effect from the...
Natco Pharma Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015
Natco Pharma Limited has informed the Exchange about Transcript
Natco Pharma Limited has informed the Exchange regarding a press release dated Jun 03, 2026, titled "NATCO Pharma Limited and Lupin Limited receive approval from U.S. FDA for Eribulin Mesylate Injecti...
Natco Pharma Limited has informed the Exchange about Copy of Newspaper Publication of Annual Audited Financial Results for the quarter and year ended March 31, 2026
Natco Pharma Limited has informed the Exchange about Link of Recording
Natco Pharma Limited has informed the Exchange about FY26 Earnings Presentation
Natco Pharma Limited has submitted to the Exchange, the Audited financial results for the quarter and year ended March 31, 2026.
Natco Pharma Limited has informed the Exchange about Schedule of meet
Natco Pharma Limited has informed the Exchange about Action(s) initiated or orders passed
Natco Pharma Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015